Hijazi Z, et al. - Among 5,275 patients with atrial fibrillation in the RE-LY trial, researchers determined the interrelationship between left ventricular hypertrophy (LVH) and cardiac biomarkers and their independent links with outcomes. Baseline plasma samples were analyzed and NT-proBNP, cardiac troponin I and T, and growth differentiation factor-15 were determined. They also used Cox models adjusted for baseline characteristics, LVH, and biomarkers. A total of 1,257 patients had LVH. A stroke episode in 165 patients was recorded, as well as 370 deaths during a median follow-up of 2 years. Findings revealed a significant association of cardiac biomarkers with LVH. LVH had no impact on the prognostic value of biomarkers for stroke and death. The presence of cardiac biomarkers was found to attenuate the prognostic information of LVH.